Scil Proteins GmbH Appoints Frank Ubags as Chief Operating Officer
Published: Dec 06, 2011
In the position of CFO, Mr. Ubags was responsible for closing a financing of EUR 24 Million in February 2011 from the Company’s existing investor, BioNet Holding. Scil Proteins is using these funds to develop two products derived from the Company’s Affilin® platform into clinical Phase I. Over the last three years, Scil Proteins’ contract manufacturing business, consisting of microbial non-GMP and GMP manufacturing, has seen strong growth with customers such as Roche, Actavis and Lundbeck. The Company plans to grow this business further by expanding its global customer base and enlarging its technology portfolio.
“We have been successfully running our CMO business since Scil Proteins’ inception and have been servicing customers for almost 10 years. However, in the past three years, our CMO business has experienced significant growth and because of this, we felt it was important to appoint a knowledgeable COO,” said Dr. Ulrike Fiedler, CEO of Scil Proteins. “I am delighted that Frank accepted the move to the position of COO, as he has become a valued member of our management team during the last few years. We believe that the experience he gained from his former positions at Rhein Biotech, where he played a key role in building the Company’s vaccine and CMO business, will be a significant benefit for Scil Proteins, particularly in his new position.”
Commenting on his own appointment, Mr. Ubags noted: “We have already identified potential areas for expanding our CMO business further and I look forward to making these plans a reality with our CMO team, which currently consists of 75 professionals.”
Melanie Käsmarker will take over the responsibility of Scil Proteins’ Finance, Procurement and Human Resource departments as Director of Finance. She has served the company over the past three years as Head of Controlling & Accounting.
About Scil Proteins
Scil Proteins is a biopharmaceutical company discovering and developing Affilin® molecules and working with industry partners in the development and manufacture of protein therapeutics and diagnostics. In addition to generating a pipeline of Affilin® therapeutics targeting cancer and other therapeutic areas, the Company has a longstanding expertise in protein production and development and offers GMP contract biomanufacturing and process development to biotech and pharma companies. With state of the art equipment, and a particular expertise at refolding proteins, the Company has an excellent track record in supplying a top level support for its partners. Scil Proteins has supported a number of different companies in process development and biomanufacturing. Scil Proteins is a well-established private company located in Halle, Germany. To learn more about Scil Proteins, please visit www.scilproteins.com
Scil Proteins GmbH
Dr. Ulrike Fiedler
t: (Germany) +49 (0) 345 27 99 63 30
t: (Germany) +49 (0) 89 52 05 92 12